Form 4: Athira Pharma's Chief Medical Officer Acquires 400,000 Stock Options

Javier San Martin, Chief Medical Officer of Athira Pharma, acquired 400,000 stock options on April 15, 2024, according to a recent SEC filing.

Summary

• An SEC Form 4 filing reveals that Javier San Martin, the Chief Medical Officer of Athira Pharma, Inc. (ATHA), acquired 400,000 stock options on April 15, 2024.
• The exercise price of these options is $2.06.
• The options vest over a period of four years, with 25% vesting on the one-year anniversary of the grant date and the remaining options vesting monthly thereafter, contingent upon continued service.
• The expiration date for these options is April 14, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation practice, and there's no indication of positive or negative implications.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. This grant aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to align executive interests with shareholder value.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could incentivize the Chief Medical Officer to drive long-term value for shareholders.
• Employees may view this as a positive sign of investment in leadership.

Key Dates